✦ LIBER ✦

Diet or diuretic? Treatment of newly diagnosed mild to moderate hypertension in the elderly

✍ Scribed by Koopman, H; Devillé, W; van Eijk, JThM; Donker, A J M; Spreeuwenberg, C

Book ID: 110047702
Publisher: Nature Publishing Group
Year: 1997
Tongue: English
Weight: 81 KB
Volume: 11
Category: Article
ISSN: 0950-9240
DOI: 10.1038/sj.jhh.1000549

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TIENILIC ACID IN THE TREATMENT OF MILD T

TIENILIC ACID IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION

✍ R. G. Walker; C. K. Yeung; A. S. P. Hua; G. W. Thomas; Judith A. Whitworth; Pris 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

Once daily propranolol in the treatment

Once daily propranolol in the treatment of mild to moderate hypertension

✍ A. P. Douglas-Jones; N. S. Baber; A. Lee 📂 Article 📅 1978 🏛 Springer 🌐 English ⚖ 336 KB

Pinacidil, a new vasodilator, in the tre

Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension

✍ V. D'Arcy; M. Laher; D. McCoy; P. Sullivan; C. H. Walsh; M. P. Hickey 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 328 KB

Nisoldipine CC and Lisinopril Alone or i

Nisoldipine CC and Lisinopril Alone or in Combination for Treatment of Mild to Moderate Systemic Hypertension

✍ Terrence D. Ruddy; J. George Fodor 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 192 KB

A comparison of lisinopril and nifedipin

A comparison of lisinopril and nifedipine in the treatment of mild to moderate hypertension

✍ B. Rogstad 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 294 KB

Evaluation of celiprolol, a new cardiose

Evaluation of celiprolol, a new cardioselective beta1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly

✍ K. D. Lamon 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 499 KB

Celiprolol hydrochloride is a cardioselective beta 1-adrenergic antagonist with partial agonist activity. The studies discussed were designed to assess celiprolol's pharmacokinetic disposition, its efficacy versus placebo and other beta blockers, its relative safety profile, and its therapeutic rati